Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 6, 2011, Pages

  Jiang, Houli ^a   Quilley, John ^a   Doumad, Anabel B ^a   Zhu, Angela G ^a   Falck, John R ^b   Hammock, Bruce D ^c   Stier Jr , Charles T ^a   Carroll, Mairead A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytochrome P 450; Epoxyeicosatrienoic acids; Hypertension; Soluble epoxide hydrolase

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; BENZOIC ACID DERIVATIVE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARCUATE ARTERY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FATTY ACID BLOOD LEVEL; HYPERTENSION; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION; WISTAR KYOTO RAT;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACIDS; BENZOIC ACID; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; ERYTHROCYTES; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 79958041570     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01267.2010     Document Type: Article

References (56)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 104: 9018-9023, 2007.
2. Barenbrock M, Spieker C, Rahn KH, Zidek W. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol 40: 241-243, 1993.
3. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
4. Bui PH, Hsu EL, Hankinson O. Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol. Mol Pharmacol 76: 1044-1052, 2009.
5. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endotheliumdependent responses. Pflugers Arch 459: 881-895, 2010.
6. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol Hypertens 11: 177-183, 2002.
7. Capdevila J, Saeki Y, Falck JR. The mechanistic plurality of cytochrome P-450 and its biological ramifications. Xenobiotica 14: 105-118, 1984.
8. Capdevila JH, Karara A, Waxman DJ, Martin MV, Falck JR, Guenguerich FP. Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem 265: 10865-10871, 1990.
9. Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC. Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol 138: 281- 283, 1987.
10. Chacos N, Capdevila J, Falck JR, Manna S, Martin-Wixtrom C, Gill SS, Hammock BD, Estabrook RW. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 223: 639-648, 1983.
11. Chen X, Patel K, Connors SG, Mendonca M, Welch WJ, Wilcox CS. Acute antihypertensive action of Tempol in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 293: H3246-H3253, 2007.
12. Cheng MK, Doumad AB, Jiang H, Falck JR, McGiff JC, Carroll MA. Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors. Br J Pharmacol 141: 441-448, 2004.
13. Fahal IH, Yaqoob M, Ahmad R. Phlebotomy for erythropoietin-induced malignant hypertension. Nephron 61: 214-216, 1992.
14. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, Campbell WB. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284: H337-H349, 2003.
15. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288-1291, 2008.
16. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
17. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, Liggett WF. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261: 15334-15338, 1986.
18. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40: 485-490, 2002.
19. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377-6381, 1989.
20. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90: 1028- 1036, 2002.
21. Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol 102: 453-458, 2008.
22. Goulitquer S, Dreano Y, Berthou F, Corcos L, Lucas D. Determination f epoxyeicosatrienoic acids in human red blood cells and plasma by GC/MS in the NICI mode. J Chromatogr B Analyt Technol Biomed Life Sci 876: 83-88, 2008.
23. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally ioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50: 825-3840, 2007.
24. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble poxide hydrolase inhibition lowers arterial blood pressure in angiotensin I hypertension. Hypertension 39: 690-694, 2002.
25. Jiang H, Anderson GD, McGiff JC. Red blood cells (RBCs), epoxyeicosatrienoic cids (EETs) and adenosine triphosphate (ATP). Pharmacol ep 62: 468-474, 2010.
26. Jiang H, McGiff JC, Quilley J, Sacerdoti D, Reddy LM, Falck JR, Zhang F, Lerea KM, Wong PY. Identification of 5,6-trans-epoxyeicosatrienoic cid in the phospholipids of red blood cells. J Biol Chem 279: 6412-36418, 2004.
27. Jiang H, Quilley J, Reddy LM, Falck JR, Wong PY, McGiff JC. Red lood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids. Prostaglandin ipid Mediat 75: 65-78, 2005.
28. Jiang H, Zhu AG, Mamczur M, Falck JR, Lerea KM, McGiff JC. Stimulation of rat erythrocyte P2X(7) receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 151: 1033-1040, 2007.
29. Jiang H, Zhu AG, Mamczur M, Morisseau C, Hammock BD, Falck JR, McGiff JC. Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. J Pharmacol Exp Ther 326: 330-337, 2008.
30. Larsen BT, Campbell WB, Gutterman DD. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci 28: 32-38, 2007.
31. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290: H491-H499, 2006.
32. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 24: 3770-3781, 2010
33. Lee JY, Azar SH. Wistar-Kyoto and spontaneously hypertensive rat blood pressure after embryo transfer into different wombs and crosssuckling. Exp Biol Med (Maywood) 235: 1375-1384, 2010.
34. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 13: 3480 3487, 2008.
35. Liclican EL, Doumad AB, Wang J, Li J, Falck JR, Stier CT Jr, Carroll MA. Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. Hypertension 54: 1284-1290, 2009.
36. Lin WK, Falck JR, Wong PY. Effect of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem Biophys Res Commun 167: 977-981, 1990.
37. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-Salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47: 87-98, 2007.
38. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 94: 2414-2420, 1994.
39. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740-F748, 2009.
40. McCallum GP, Weedon AC, Krug P, Bend JR. Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver. J Pharmacol Exp Ther 278: 1188-1194, 1996.
41. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 51: 1379-1385, 2008.
42. Pomposiello SI, Carroll MA, Falck JR, McGiff JC. Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension 37: 887-893, 2001.
43. Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC. 5,6- Epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension 42: 548-554, 2003.
44. Pratt PF, Li P, Hillard CJ, Kurian J, Campbell WB. Endotheliumindependent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol 280: H1113-H1121, 2001.
45. Revermann M. Pharmacological inhibition of the soluble epoxide hydrolase- from mouse to man. Curr Opin Pharmacol 10: 173-178, 2010.
46. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 33: 424-428, 1999.
47. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 106: 5171-5176, 2009.
48. Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, Hammock BD, Paton JF, Raizada MK. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J 19: 626-628, 2005.
49. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat 20: 941-956, 2010.
50. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res Suppl 50: S52-S56, 2009.
51. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43: 55-90, 2004.
52. Vaz AD, McGinnity DF, Coon MJ. Epoxidation of olefins by cytochrome P450: evidence from site-specific mutagenesis for hydroperoxoiron as an electrophilic oxidant. Proc Natl Acad Sci USA 95: 3555-3560, 1998.
53. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434-438, 2003.
54. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286: F720-F726, 2004.
55. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992-998, 2000.
56. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322: 76-86, 1995.